Huber Expands and Acquires Van der Heijden Labortechnik GmbH
The 2016 fi nancial year proved outstandingly successful for Peter Huber Kältemaschinenbau AG. Recording double-digit growth, the company was acclaimed as best employer and a top 100 innovator, receiving the Grand Prix for Medium-Sized Companies along with the Environmental Award of the State of Baden-Wurttemberg.
From left to right: Beatrice Geiler (Member of the Board Huber), Joachim Huber (Vice Chairman Huber), Mirko Laskowski (CEO VDH), Andrej Kepler (CEO VDH), Bärbel Huber (Member of the Board Huber), Christoph Plagens (Previous owner VDH), Frank Rieger (Supervisory Board Huber), Daniel Huber (Chairman Huber)
Fingerprint Screening Receives £3 Million Investment
Intelligent Fingerprinting, a UK company developing a portable fi ngerprint-based drug screening system, has secured a further £3 million of funding from an expanded group of private US and UK investors. The investment will support the early commercialisation of the fi rst drug screening panel and include manufacturing scale-up and validation of the company’s fi rst products made at its dedicated facility in Cambridge. These products are to be used widely in pilot programmes within the UK and US.
Commenting on the investment, Intelligent Fingerprinting’s Chairman Philip Hand said: “2017 is set to be an important year for the business as we transition from running successful pilot projects to bringing our revolutionary technology to the broader market. The fi rst product of its kind in the world, our mobile drug screening system is easy-to-use, non-invasive and works in minutes by analysing sweat from a fi ngerprint. This latest investment will enable the acceleration of activities across the business, including both our sales and marketing programmes as well as our ongoing FDA approval activities in the USA.”
41777pr@reply-direct.com Dr Igor Matushansky
Dr Igor Matushansky, MD PhD has joined Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, as Global Head, Research and Development.
Dr Matushansky was previously with Daiichi Sankyo as Global Head of Translational Development for Oncology, where he led the international research unit focused on early oncology therapeutic programs, strategy and development. He worked as Global Head for Clinical and Scientifi c Development at Novartis’ iGene & Cell Therapy Unit and was a Global Clinical Program Lead within its Oncology Translational Medicine Unit.
Chairman of the Board Daniel Huber is pleased with the successes: “The goal of becoming the innovation and technology leader for highly-precise temperature control is what drives us forward. The development of our company demonstrates that the investments and the strategic orientation were just right. Our philosophy is: ‘We do not have to be one of the biggest, but we want to be the best! Our entire product portfolio and the numerous customised special solutions are attuned to this corporate philosophy. For example, our technical expertise is based on our core disciplines of thermodynamics and microelectronics. We conduct basic research in these areas (also in cooperation with the Offenburg and Karlsruhe Universities) and develop optimised and sustainable solutions for customers around the world.”
With plans to support market growth by doubling production at its Offenburg site, Huber’s acquisition of Van-der-Heijen Labortechnik
GmbH Dörentrup, a manufacturer of circulation coolers and system separators (water-water heat exchangers), has further expanded the company’s product range. Established particularly in cooling equipment for analytical instruments and systems, Heijden’s particular strength lies in provision of individual confi gurations or customised solutions to master customers’ temperature control tasks.
Founded more than 40 years ago with sound operational infrastructure based on ecological principles, Daniel Huber explained why Van- der-Heijden Labortechnik GmbH was a good choice: “Their product portfolio complements the portfolio of our group. In analytics and when it comes down to the cost-effective dissipation of process heat, Van-der-Heijden is already one of the best. The chemistry is right: The people and the corporate philosophies fi t each other”
The former CEO and company owner Christoph Plagens will continue to support the fi rm for another 3-4 years as the mentor and sales manager. Mirko Laskowski and Andrej Kepler have been appointed as the new CEOs.
42003pr@reply-direct.com
Hookipa Biotech Welcomes Head of R&D
Previously a Professor at the Columbia University Medical Center where he focused on the molecular biology, translational opportunities and clinical trials in sarcomas, he is currently an Adjunct Professor of Medical Oncology, Columbia University. He gained his MD and also PhD in Molecular Biology at the Albert Einstein College of Medicine and completed fellowships in Medical Oncology and Cancer Biology at the Memorial Sloan Kettering Cancer Center.
Commenting on the appointment, Hookipa’s CEO, Mr Joern Aldag said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma coupled with his signifi cant immuno-oncology expertise will be transformative to Hookipa as we expand our Company from prophylactic to therapeutic immuno-oncology focused therapies. His impressive and extensive professional background makes him a perfect fi t for our leadership team during an important time in our Company’s growth. I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”
Dr Matushansky said, “TheraT® has real potential both alone and in combination with other immune-modulators and/or targeted therapies to improve not only the current clinical outcomes but the quality of life for a wide array of cancer patients. It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”
42185pr@reply-direct.com
Insourcing Model Improves Operational Efficiency
French Contract Research Organisation (CRO) NovAliX is to deliver on-site discovery chemistry services to support small molecules drug discovery programs under a multi-year insourcing agreement with Belgian biopharmaceutical company UCB Biopharma.
NovAliX offers a collaborative model for insourcing operations in chemistry, biophysics and drug discovery. Its model is based on the proximity created by the client’s and NovAliX’s teams both operating on the client’s site. This proximity allows faster turnaround time and improves cost effi ciency, thanks to the optimal use of existing available research laboratories and equipment at the client’s premises. This insourcing model also enables local teams at various sites to share best practices to improve effi ciency.
“This new collaborative agreement acknowledges not only the benefi ts of insourcing as a cost-effi cient sourcing approach, it also proves that it’s a scientifi cally sound model,” said Stephan Jenn, president of NovAliX. “Our agreement with UCB shows that pharma companies today focus on new innovative sourcing models.”
NovAliX currently works with fi ve partners from the top 50 pharma companies as well as seven research sites across Europe, all operating on the co-located research program model.
42005pr@reply-direct.com
Service Provides Option for Outsourcing Compound Management
Merz Pharmaceuticals GmbH, part of the Merz Pharma Group, has entered into a Master Service Agreement (MSA), under which BioAscent provides management service.
a comprehensive of Merz facility outsourced compound
This includes responsibility for the storage, plating, distribution, logistics and tracking
Pharmaceutical’s compounds,
supplying screen-ready plates as and when they are required. BioAscent’s
Newhouse provides a scalable, secure
infrastructure, which can handle solid and liquid compounds in a wide range of tubes and microplates between ambient and -20°C.
“Having reviewed the tender submissions, it was clear that BioAscent’s capabilities and management team were ideal for our requirements”, said Dr Ulrich Abel, Principal Scientifi c Expert Pharmaceutical Chemistry at Merz. “Having made the decision to outsource our compound management to BioAscent, we have been very happy with the service; we have complete control and our requests are managed accurately and promptly. We were also really pleased with the ease of the hand-over process, which was less than one week, during which there was no overall disruption to our screening workfl ow.”
42004pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
